Residual Disease Evaluation of Resected NSCLC by cirDNA Analysis

Inclusion Criteria: * Age: 18 years or older * Patients with a resectable NSCLC * Definite stage I to IIIA * Performance status of 0, 1 or 2 * Normal end organ functions * Written and signed informed consent form * Subjects must be covered by public health insurance. Exclusion Criteria: * Any previous systemic neoadjuvant treatment: targeted therapy, chemotherapy, immune checkpoint blockade * Previous radiotherapeutic neoadjuvant treatment * Resection margins R1 and R2 * Non-invasive lung carcinoma * Multiple primary lung cancer. * Previous malignancy during the past 3 years (except non-melanomatous skin cancer) * Preexisting interstitial lung disease * known HIV, active viral B hepatitis or C hepatitis * Patient with any other situation responsible for cirDNA rate increasing (active auto-immune disease, 10 days following blood transfusion) * Patient unable to attend all scheduled visits * Woman of childbearing age without efficient contraception, breastfeeding * Patient with a legal protection measure (guardianship, curatorship) * Vulnerable patient protected by law